BRKM5:BMFBOVESPABraskem S.A. Pfd A Analysis
Data as of 2026-03-17 - not real-time
R$12.19
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at R$12.19, comfortably above the 20‑day SMA of 10.78 and the 50‑day SMA of 9.69, indicating a clear bullish price structure. Both averages sit above the 200‑day SMA of 8.65, reinforcing long‑term upward momentum. Momentum gauges are supportive, with the RSI at 63 (above 50 but still shy of overbought territory) and a bullish MACD histogram of 0.07. Volume trends are increasing, and the price is respecting a technical support near R$8.89 while facing resistance around R$13.78. The market sentiment indicator reads 79.45 (“Extreme Greed”), suggesting strong short‑term demand.
However, the fundamentals are markedly weak: trailing EPS is a negative -6.65 and forward EPS remains negative at -3.91. Gross margin is only 4.4% and operating margin is negative 9.7%, with a net loss margin of -7.1%. The balance sheet shows a staggering debt load of roughly R$63.2 bn versus cash of R$7.4 bn, and book value per share is negative at -4.43. Valuation multiples are distorted (PE and PB are negative) and the current price exceeds analyst median target of R$10.25 and mean target of R$11.37, implying the stock is overvalued. No dividend is paid, confirming a lack of sustainable shareholder returns.
However, the fundamentals are markedly weak: trailing EPS is a negative -6.65 and forward EPS remains negative at -3.91. Gross margin is only 4.4% and operating margin is negative 9.7%, with a net loss margin of -7.1%. The balance sheet shows a staggering debt load of roughly R$63.2 bn versus cash of R$7.4 bn, and book value per share is negative at -4.43. Valuation multiples are distorted (PE and PB are negative) and the current price exceeds analyst median target of R$10.25 and mean target of R$11.37, implying the stock is overvalued. No dividend is paid, confirming a lack of sustainable shareholder returns.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish SMA crossover and MACD alignment
- RSI in healthy range with rising volume
- Extreme greed sentiment supporting upward push
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Negative earnings and high leverage
- Price above analyst targets indicating overvaluation
- Volatile price swings (84% 30‑day volatility)
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Unsustainable debt burden and negative cash flow
- Consistently negative margins and zero dividend
- Fundamental overvaluation relative to long‑term value
Key Metrics & Analysis
Financial Health
Revenue Growth-18.60%
Profit Margin-7.11%
P/E Ratio-3.1
ROA-2.76%
P/B Ratio-2.7
Op. Cash FlowR$-2484000000
Free Cash FlowR$-7746124800
Technical Analysis
TrendBullish
RSI63.3
SupportR$8.89
ResistanceR$13.78
MA 20R$10.78
MA 50R$9.69
MA 200R$8.65
MACDBullish
VolumeIncreasing
Fear & Greed Index79.45
Valuation
Target PriceR$11.37
Upside/Downside-6.75%
GradeOvervalued
TypeValue
Risk Assessment
Beta0.91
Volatility84.65%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.